Can a new cosmetic pass the sensitive skin test?
NCT ID NCT07771998
First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time
Summary
This trial evaluates whether Blancy Pro, a cosmetic product, is safe and gentle enough for people with sensitive skin. About 33 women aged 18 to 60 with clinically confirmed sensitive skin will use the product, and researchers will check for any skin or eye irritation. The goal is to see if the product can be used without causing discomfort or adverse reactions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Blancy Pro, a cosmetic product
- What this could lead to
- If successful, this could support Blancy Pro as a well-tolerated cosmetic option for people with sensitive skin, potentially reducing irritation and discomfort.
- What could go wrong
- This is a small, early-stage safety study, not a test of effectiveness. Results may not apply to all skin types, and individual reactions can still occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 33 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Female participants aged 18 to 60 years. * Participants with any skin type, with at least 25% representation of each skin type. * Participants with sensitive skin, clinically confirmed by the Stinging Test. * Intact skin in the assessment area. * Willingness to comply with all study procedures and attend scheduled visits and assessments. * Ability to understand, provide written informed consent, and sign the Informed Consent Form (ICF). Exclusion Criteria: * Pregnant or breastfeeding women, or women at risk of becoming pregnant during the study. * Use of anti-inflammatory, immunosuppressive, or antihistamine medications within 3 weeks prior to screening. * Skin marks or conditions in the study area that may interfere with the evaluation of skin reactions, including vascular malformations, scars, excessive hair growth, multiple nevi, or sunburn. * History of atopic disease or allergy to cosmetic products. * Active skin diseases and/or lesions in the assessment area or elsewhere on the body. * Immunosuppression due to medication use or active disease. * Uncontrolled endocrine disorders. * Relevant medical history or current evidence of alcohol or drug abuse. * Known history or suspected intolerance to products of the same category as the investigational product. * Intense sun exposure within 15 days prior to assessment. * Aesthetic or dermatological treatments within 4 weeks prior to assessment. * Any other condition that, in the investigator's opinion, may justify exclusion from the study. Reasons for exclusion will be documented in the clinical record. * Participants with entropion, ectropion, hordeolum (stye), conjunctivitis, uveitis, or other active ocular diseases at screening. * Participants with corneal ulceration, blepharitis, meibomitis, pterygium, trichiasis, distichiasis, or other moderate to severe ocular disorders. * Initiation of contact lens use within 1 week prior to screening. * Use of ophthalmic products, including eye drops and/or ophthalmic ointments, within 3 weeks prior to screening. * Any other ocular condition that, in the investigator's opinion, may justify exclusion from the study. Reasons for exclusion will be documented in the clinical record.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Sensitive skin are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Grupo Medcin
RECRUITINGOsasco, São Paulo, 06023-070, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Will these 18 beauty products irritate your skin? a patch test seeks answers
- Can a daily collagen drink fix dry skin? new trial aims to find out
- New cream promises relief for dry, cracked skin in just 28 days
- Can LED lights soothe sensitive skin?
- Baby skin study reveals hidden differences in sensitive skin
- New Anti-Aging cream shows promise for sensitive, wrinkled skin